

# Voglibose

Catalog No: tcsc2865

Available Sizes

Size: 50mg

Size: 100mg

**Specifications** 

CAS No:

83480-29-9

#### Formula:

 $C_{10}H_{21}NO_7$ 

#### Pathway:

Others

#### **Target:**

Others

#### Purity / Grade:

>98%

## **Observed Molecular Weight:**

267.28

### **Product Description**

Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against  $\alpha$ -glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.

Target:  $\alpha$ -glucosidases

glibose can inhibit the intestinal  $\alpha$ -glucosidases, which are responsible for the digestion of disaccharides such as maltose and

Copyright 2021 Taiclone Biotech Corp.



sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose [1]. Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocininduced diabetic rats [2]. Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice [3].



#### All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.